Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Background Florbetapir F 18 (F-AV-45) is a positron emission tomography imaging ligand for the detection of amyloid aggregation associated with Alzheimer disease. Earlier data showed that florbetapir F 18 binds with high affinity to β-amyloid (Aβ) plaques in human brain homogenates (Kd=3.7 nM) and has favorable imaging pharmacokinetic properties, including rapid brain penetration and washout. This study used human autopsy brain tissue to evaluate the correlation between in vitro florbetapir F 18 binding and Aβ density measured by established neuropathologic methods. Methods The localization and density of florbetapir F 18 binding in frozen and formalin-fixed paraffin-embedded sections of postmortem brain tissue from 40 patients with a varying degree of neurodegenerative pathology was assessed by standard florbetapir F 18 autoradiography and correlated with the localization and density of Aβ identified by silver staining, thioflavin S staining, and immunohistochemistry. Results There were strong quantitative correlations between florbetapir F 18 tissue binding and both Aβ plaques identified by light microscopy (Silver staining and thioflavin S fluorescence) and by immunohistochemical measurements of Aβ using 3 antibodies recognizing different epitopes of the Aβ peptide. Florbetapir F 18 did not bind to neurofibrillary tangles. Conclusions Florbetapir F 18 selectively binds Aβ in human brain tissue. The binding intensity was quantitatively correlated with the density of Aβ plaques identified by standard neuropathologic techniques and correlated with the density of Aβ measured by immunohistochemistry. As Aβ plaques are a defining neuropathologic feature for Alzheimer disease, these results support the use of florbetapir F 18 as an amyloid positron emission tomography ligand to identify the presence of Alzheimer disease pathology in patients with signs and symptoms of progressive late-life cognitive impairment.

What this study adds

Evidence grade: Low

The record lists 40 participants. It does not by itself show how accurate a scan is in a living patient, and it is an imaging agent, not a treatment.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Choi, SR., Schneider, J. A., Bennett, D. A., Beach, T. G., Bedell, B. J., Zehntner, S. P., et al. (2012). Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer disease and associated disorders. https://doi.org/10.1097/wad.0b013e31821300bc

Vancouver

Choi SR, Schneider JA, Bennett DA, Beach TG, Bedell BJ, Zehntner SP, et al. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer disease and associated disorders. 2012. doi:10.1097/wad.0b013e31821300bc. PMID: 22354138.

BibTeX

@article{choi2012-22354138,
  author  = {Choi, SR. and Schneider, J. A. and Bennett, D. A. and Beach, T. G. and Bedell, B. J. and Zehntner, S. P. and Krautkramer, M. J. and Kung, H. F. and others},
  title   = {{Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2012},
  doi     = {10.1097/wad.0b013e31821300bc},
  pmid    = {22354138},
  url     = {https://doi.org/10.1097/wad.0b013e31821300bc}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In brain tissue from 40 people examined after death, how strongly the PET tracer florbetapir F 18 bound matched how much amyloid plaque was found by silver staining, thioflavin S staining and three different Aβ antibodies, and it "did not bind to neurofibrillary tangles." This is tissue-level support for using the tracer to detect amyloid. It does not by itself show how accurate a scan is in a living patient, and it is an imaging agent, not a treatment.

Study details

How this study scored 46/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 3 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 1 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 46 of 100.46 of 100 points earned54 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders)
Journal's citation record 1 / 4 Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2012 — within 20 year(s) of the newest study here
Sample size 1 / 4 40 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 129 times (OpenAlex, 2026-10-10)
Citations per year 3 / 5 8.1 citations a year over 16 year(s) since 2012
Impact for its field and year 3 / 6 Cited 6.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 9 other studies in this library
Still being cited 1 / 4 Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Christopher M. Clark: h-index 73 (OpenAlex, whole career)
Institution's track record 1 / 3 McGill University: institution h-index 1,373 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 22354138)
Free to read 0 / 2 Behind a paywall — scores zero
Total 46 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

9 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Biomarkers from nearby years

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →